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The single-celled apicomplexan parasite Plasmodium falciparum is responsible for the
majority of deaths due to malaria each year. The selection of drug resistance has been a
recurring theme over the decades with each new drug that is developed. It is therefore
crucial that future generations of drugs are explored to tackle this major public health
problem. Cyclic GMP (cGMP) signaling is one of the biochemical pathways that is being
explored as a potential target for new antimalarial drugs. It has been shown that this
pathway is essential for all of the key developmental stages of the complex malaria
parasite life cycle. This gives hope that targeting cGMP signaling might give rise to
drugs that treat disease, block its transmission and even prevent the establishment
of infection. Here we review previous work that has been carried out to develop and
optimize inhibitors of the cGMP-dependent protein kinase (PKG) which is a critical
regulator of the malaria parasite life cycle.
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INTRODUCTION
Malaria kills more than 400,000 people each year, mainly young children in Africa (WHO,
2019), despite the availability of effective control measures and drug treatments. The selection
and spread of drug resistant malaria parasites has made the development of new interventions
an urgent priority so that increases in clinical cases and mortality can be avoided. High
throughput screening of large chemical libraries has led to a number of promising new
candidate antimalarial drugs that are progressing through clinical trials, but we cannot be
sure how many of these will be rolled out as new treatments. It is therefore necessary
that we continue to explore alternative drug targets that operate through different modes
of action and progress the next generation of drugs to combat the serious problem of
drug resistance.
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One of the targets that has received significant attention
in recent years is the cyclic GMP (cGMP)-dependent protein
kinase (PKG) which is the central regulator of cGMP signaling
in malaria parasites (Baker et al., 2017a; Cabrera et al., 2018).
Cyclic GMP is an intracellular messenger molecule that is
synthesized from GTP by guanylyl cyclase and broken down
(hydrolyzed) by phosphodiesterases (PDEs). The cellular levels
of cGMP are balanced by the opposing activities of these two
enzyme classes which are in turn regulated by as yet unknown
mechanisms. As cGMP reaches a threshold concentration in
the cell, it binds to and activates PKG which can then
phosphorylate its many intracellular protein substrates. The
cGMP signaling pathway is present in most organisms and
controls myriad processes across the animal kingdom ranging
from transducing environmental signals (Bosgraaf and Van
Haastert, 2002) and mediating locomotion in some protozoa
(Linder et al., 1999) to controlling cardiovascular function
(Bork and Nikolaev, 2018) and regulating phototransduction in
humans (Stryer, 1986).
Protozoan parasites of the genus Plasmodium which cause
malaria have a complex life cycle, with specialized forms adapted
to both establishing infection and proliferation within the
mammalian host and specific forms which mediate transmission
to and from the Anopheles mosquito vector. We and others
have demonstrated that cGMP signaling plays an essential role
in all of the important stages of the Plasmodium life cycle
(McRobert et al., 2008; Taylor et al., 2008, 2010; Moon et al.,
2009; Falae et al., 2010; Collins et al., 2013; Brochet et al.,
2014; Lakshmanan et al., 2015; Govindasamy et al., 2016;
Koussis et al., 2020) indicating that targeting this pathway with
a drug would interrupt the life cycle making it plausible to
treat disease, block transmission and even to prevent infection.
Cyclic GMP signaling through PKG is required to stimulate
the mobilization of calcium from internal stores which in turn
activates life cycle stage-restricted calcium-dependent protein
kinases (CDPKs) to continue the signaling cascade and stimulate
cell function through reversible protein phosphorylation (Dvorin
et al., 2010; Brochet et al., 2014; Fang et al., 2018). PKG is also
known to stimulate a protease cascade in blood stage parasites
which it initiates by triggering the release of the subtilisin-
like protease SUB1 from apical organelles called exonemes
(Dvorin et al., 2010; Collins et al., 2013; Thomas et al., 2018).
Numerous P. falciparum schizont proteins have been identified
which require the activity of PKG to be phosphorylated (Alam
et al., 2015), but it is not known how these mediate its role in
merozoite egress.
THE IMPORTANCE OF A SMALL
GATEKEEPER RESIDUE
A crucial structural feature of the parasite PKG underpins firstly
the experimental approach that has been taken to study the
function of PKG and secondly the utility of the enzyme as a drug
target because this structural feature is not present in human
PKG enzymes. This unique feature is simply the existence of
a relatively small amino acid residue (threonine, Thr) in the
so-called gatekeeper position of this protein kinase (McRobert
et al., 2008). Human PKGs (and the majority of serine/threonine
kinases) have a bulkier amino acid (e.g., Methionine, Met) at
this position (Huang et al., 2010). The crucial consequence
of having a small residue in this position is that it makes
available a small hydrophobic pocket (the gatekeeper pocket) that
adjoins the ATP-binding pocket (Donald et al., 2002; McRobert
et al., 2008). Certain classes of small molecule ATP-competitive
inhibitors can also occupy this small adjacent pocket with a
protruding side chain which thereby confers exquisite inhibitor
selectivity (Gum et al., 1998; Donald et al., 2002; Baker et al.,
2017b). The presence of a bulky residue in the gatekeeper
position prevents inhibitor access to the gatekeeper pocket
and renders the kinase (and cell) insensitive to the inhibitor
(Donald et al., 2002; McRobert et al., 2008). Exploitation of a
kinase gatekeeper pocket to generate selective compounds has
been used to tackle human disease by, for example, targeting
p38α MAP kinase to inhibit cytokine-mediated inflammatory
responses (Dominguez et al., 2005).
A research group at Merck working on the related parasite
Eimeria (and the related genetically tractable Toxoplasma)
first identified and utilized the small gatekeeper residue of
apicomplexan PKGs to investigate the function of the enzyme
in coccidian parasites (Donald et al., 2002) and importantly
to demonstrate on-target activity of a potent anticoccidial
agent they had identified by high throughput screening [a tri-
substituted pyrrole, compound 1 (Gurnett et al., 2002)] and
that of a more specific PKG inhibitor (an imidazopyridine,
compound 2, Figure 1) derived from a medicinal chemistry
effort (Donald et al., 2006). Importantly, 1 was also shown to
have inhibitory activity against malaria parasites (Diaz et al.,
2006) and has (along with 2) subsequently been used, in
conjunction with transgenic lines expressing inhibitor resistant
PKG alleles, to unequivocally determine the function of PKG
throughout the malaria parasite life cycle (Baker et al., 2017a)
(Figure 2). In the first such report, McRobert and colleagues
generated a Plasmodium falciparum transgenic cell line in which
the small gatekeeper residue (Thr618) was substituted with a
bulkier glutamine (Gln) by allelic replacement at the endogenous
PKG locus. Crucially, parasites expressing PKG with the bulky
gatekeeper residue were several-fold less sensitive to compounds
1 and 2 than parental wild type parasites (McRobert et al., 2008).
This approach of comparing the effects of a PKG inhibitor on
wild type and gatekeeper mutant parasites has demonstrated
an essential role for PKG in blood stage merozoite egress
from red blood cells (Collins et al., 2013), release of male and
female gametes from red blood cells (gametogenesis) (McRobert
et al., 2008), maturation and motility of ookinetes (that develop
following fertilization and zygote formation) (Moon et al., 2009;
Brochet et al., 2014), motility of sporozoites and invasion of
hepatocytes as well as release of merozoites from late liver
stage parasites (Falae et al., 2010; Govindasamy et al., 2016).
This combined chemical and genetic approach has demonstrated
clearly that cGMP signaling mediated by PKG plays a vital
role in a number of critical life cycle stage transitions and has
simultaneously provided important data validating PKG as a
tractable antimalarial drug target.
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FIGURE 1 | Representative structures of PKG inhibitors mentioned in the text.
PKG INHIBITORS OFTEN HAVE
STRUCTURALLY-RELATED SECONDARY
TARGETS
As previously mentioned, the gatekeeper mutant approach has
facilitated functional analysis of PKG in apicomplexan parasites
and drug target validation for PKG. However, the approach also
inherently allows determination of whether PKG is the primary
target of a PKG inhibitor of interest and also whether there
are significant secondary targets (Donald et al., 2002; Wiersma
et al., 2004; McRobert et al., 2008). It is important to realise
that IC50 values (derived from purified recombinant PKG) of
compounds 1 and 2 for PKG are several logs different for
wild type and gatekeeper mutant PKG, suggesting that these
inhibitors do not easily access the gatekeeper pocket when a
bulky gatekeeper residue is present. However, when EC50 values
are compared (derived from e.g., blood stage growth inhibition
assays) for different PKG inhibitors, it is clear that compared to
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FIGURE 2 | Schematic showing that inhibitors bind effectively to the malaria parasite PKG due to the presence of a small gatekeeper residue (threonine, T), which
upon mutation to a bulkier residue (glutamine, Q), prevents inhibitor binding.
IC50 levels, the difference is relatively low (several-fold rather
than log-fold) (Donald et al., 2002; Baker et al., 2017b). This at
first is perplexing, but actually reflects the fact that some PKG
inhibitors have significant secondary targets that they bind to in
the cell. This was first recognized in the earlier studies by the
Merck team working on compounds 1 and 2 with Eimeria and
Toxoplasma (Donald et al., 2006) who identified both CDPK1 and
the alpha isoform of casein kinase 1 (CK1) as secondary targets
of compound 2. Importantly, it has proved possible by exploring
Structure-Activity-Relationship studies (SAR) to generate PKG
inhibitors with EC50 values that are also several logs different
between wild type and gatekeeper parasites indicating that they
are highly specific for PKG and that only very low levels of
binding to secondary targets in the parasite and importantly the
host occur (Baker et al., 2017b).
PKG ANTIMALARIAL DRUG DISCOVERY
PROJECTS
Baker et al. (2017b) reported a PKG inhibitor development
program using the Merck anticoccidial imidazopyridine
compound 2 (ML1) as a start point. This resulted in the
generation of more potent and selective analogs. The most
promising compound 3 (ML10, Figure 1) has an IC50 value of
160 pM against recombinant wild type P. falciparum PKG and
of 29.5 µM against gatekeeper mutant PKG in which threonine
618 was replaced by a glutamine. Activity against a panel of 80
human kinases (including 14 small gatekeeper kinases) was low
when tested at 100 nM which is >600-fold the IC50 value against
recombinant P. falciparum PKG. Of note, activity against human
PKGI and PKGII isoforms was also very low as expected since
they have bulky gatekeeper residues. 3 also had a clean in vitro
cytotoxicity profile when tested against HepG2 cells and other
mammalian cell lines. The EC50 value of 3 in 72-hour blood
stage growth inhibition assays using wild type parasites (clone
3D7) was 2.1 nM and was >1,100-fold higher (EC50 = 2.4 µM)
in gatekeeper parasites. This demonstrates that 3 is highly
specific for PKG and that only very low levels of binding to
secondary targets occurs which holds promise for developing a
drug that selectively targets PKG. Furthermore, this compound
has an EC50 of 41.3 nM in a standard membrane feeding assay
(SMFA) which measures the ability of an inhibitor to block
development of oocysts in mosquitos. The inhibitory activity
reflects the known essential role of PKG in male and female
gamete formation and in ookinete development and motility.
Importantly this study also provided in vivo proof of concept for
PKG as an antimalarial drug target by utilizing a P. falciparum
humanized SCID mouse model which demonstrated that
3 reduced blood stage parasitaemia to undetectable levels.
However, this was achieved by orally dosing with 3 twice daily for
4 days with 100 mg/kg which is a high dose compared with some
other candidates undergoing pre-clinical and clinical testing.
To gain insight into the detailed molecular interaction of this
chemical series with Plasmodium PKG and to inform future
medicinal chemistry optimization efforts, 3 (ML10) and the
Merck compound 2 (ML1) were each co-crystallized with P. vivax
PKG. This protein proved more amenable to co-crystallization
studies but is a good surrogate for the P. falciparum PKG because
the orthologues share 92% sequence identity and alignment
of the apo structures of the kinase domains show a deviation
from each other by a root-mean-square distance of only 0.3 Å.
(Baker et al., 2017b). The previously predicted interaction of the
fluorophenyl moiety of the chemical series with the gatekeeper
pocket (Donald et al., 2002) (on which the chemical genetic
approach is based) was confirmed for both compounds and the
high degree of selectivity of 3 (ML10) could be explained by the
co-structures which included a more pronounced exploitation
of the gatekeeper pocket and beyond by 3 than 2, with the
sulphonamide group of 3 extending into an additional cavity
not reached by 2 (Baker et al., 2017b). The compound-free
P. falciparum and P. vivax PKG full length structures obtained
as part of this study were the first reported from any organism
and contributed important insight into the mechanism by which
the PKG is activated by cGMP (El Bakkouri et al., 2019).
One drawback of specific PKG inhibitors is that they
are characterized by a moderate/slow killing rate in parasite
reduction ratio (PRR) assays similar to that of pyrimethamine
(Baker et al., 2017b; Matralis et al., 2019; Penzo et al., 2019). This
is thought to be due to the fact that PKG is active within a very
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narrow temporal window of blood stage development (perhaps
less than three hours) just prior to egress, which is thought to
persist until completion of invasion (Taylor et al., 2010; Koussis
et al., 2020). Specific PKG inhibitors have no activity against
parasites outside of this window (Taylor et al., 2010).
Progress has also been reported to further explore and develop
the imidazopyridine scaffold to improve key physicochemical
parameters whilst retaining potency against blood stages. One
aspect of this work focused on modification of the fluorophenyl
moiety (that interacts with the gatekeeper pocket) of a set
of bicyclic compounds and resulted in improved lipophilicity
and in vitro ADME properties (Large et al., 2019a,b). For
example, measured LogD could be improved from 2.4 (for
compound 2) to 1.5 in key analogs (compound 4, Figure 1).
In addition, stability was found to be moderate for compound
2 with 52% of this compound remaining after a 40-minute
incubation with liver mouse microsomes. This liability was
significantly improved by either appropriately substituting the
amino group of 2 (compound 5, Figure 1) or by applying
scaffold hopping approaches (compound 6, Figure 1). A parallel
study also sought to optimize a set of monocyclic compounds
(based on Merck trisubstituted pyrrole compound 1 that
was developed to treat Eimeria infection in chickens), with
the aims of improving structural alerts of the scaffold and
increasing selectivity against human kinases. The design of
the new molecules involved initially the replacement of the
heteroaromatic pyrrole ring of 1 with its respective isostere
thiazole followed by the replacement of the pyridine ring of 1
with that of 2-aminopyrimidine group existing in compound
2. As a result, the trisubstituted thiazole series was generated.
Excellent selectivity over human kinases was obtained in this
series by modification of the 4-fluorophenyl group (Tsagris
et al., 2018). The best selectivity was achieved by the 4-fluoro-
3-sulfonamidophenyl group (compound 7, Figure 1) which
was also found to contribute significantly to the excellent
PKG selectivity exhibited by 3. Compound 7 did not show
inhibition across a set of 80 human kinases when measured at
a concentration 50 times higher than biochemical IC50 against
recombinant PfPKG. In addition, 7 showed an outstanding
stability in both mouse and human microsomes (89 and 95%
compound remaining, respectively, after 40 min of incubation),
a remarkable aqueous solubility and LogD value (190 µM
and 1.9, respectively) and good permeability (57 nm/s in
the PAMPA assay).
To identify new chemical series that might overcome some
of the limitations of existing PKG inhibitor scaffolds, a high
throughput assay was developed to screen the GlaxoSmithKline
Full Diversity collection of 1.7 million compounds in partnership
with the Tres Cantos Open Lab Foundation. This identified
nine clusters of interesting PKG inhibitor chemotypes including
four clusters of trisubstituted heterocycles. The most interesting
of these was a series of thiazoles that showed good potency
against blood stage parasites and retained activity against
gametogenesis as expected for compounds with low IC50 values
against recombinant PKG enzyme activity. Hit expansion was
performed using an available collection of more than 3,000 GSK
thiazole derivatives. Measurement of EC50 values in 48- and
72-hour blood stage parasite growth inhibition assays indicated
that some of the analogs might bind to additional targets apart
from PKG. Specific PKG inhibitors exhibit a marked increase
in EC50 in the 48-hour assay that reflects the narrow window
of activity mentioned above. The existence of additional targets
was confirmed using a chemoproteomic approach utilizing
Kinobeads-based chemical proteomics. This identified additional
targets including CDPK1, CDPK4, and NEK1 as additional
targets for the thiazole derivatives studied (Penzo et al., 2019).
Thiazoles have previously been developed by GSK as BRAF
kinase inhibitors. For instance, Dabrafenib is used to treat a
type of melanoma (Rheault et al., 2013) and it showed good
selectivity against other human kinases with relatively mild
toxicity (Falchook et al., 2014).
A medicinal chemistry project was subsequently carried out to
further explore the potential of the thiazole series as antimalarials.
The main goal of this research was to develop fast-kill agents
given that the thiazole derivative 7 (Figure 1) developed in
preceding studies still exhibits a moderately slow parasite killing
rate. Toward this end, a chemical diversity SAR study was
explored at all possible positions of the thiazole core ring,
accompanied by isosterism approaches aiming at refining the
structural determinants conferring fast-acting potency as well as
favorable biopharmaceutical properties at the same time. Some
of the compounds generated (compounds 8–10, Figure 1) had a
very fast speed of kill comparable to that of artesunate which is
most likely due to inhibition of additional targets. Furthermore,
8–10 exhibited potent transmission blocking activity, attributed
possibly to their potent PKG inhibitory activity, and desired
ADMET properties (aqueous solubility, permeability, human
serum albumin binding, metabolic stability). Compound 10
also showed an improved cytotoxicity (using HepG2 cells) and
cardiotoxicity (hERG inhibition) profile compared to compounds
7–9. Again, Kinobeads profiling was used to identify these targets
and the most likely candidate conferring the fast killing properties
is a protein kinase called SRPK2 (CLK2) which is currently
under investigation. This kinase and others identified in both
chemoproteomic studies are amongst the relatively small number
of Plasmodium kinases that have small gatekeeper residues which
explains why they can bind to PKG inhibitors that exploit
the gatekeeper pocket. These results raise the possibility of
optimizing one of the thiazole leads 8–10 which combines the
desirable properties of a PKG inhibitor with the fast killing
properties conferred by inhibition of an additional target, likely
CLK2 (Matralis et al., 2019).
In another study Green and colleagues reported a series of
imidazopyridazine inhibitors that showed potent activity against
the P. falciparum calcium-dependent protein kinase CDPK1
in vitro (Ansell et al., 2014). Class 1 of this series (with a
pyrimidine linker between the core and the substituted amine)
exhibited activity against late P. falciparum schizonts and one
of the compounds (Compound 11, Figure 1) had an EC50
value of 23 nM. However, the EC50 in the P. falciparum
PKG T618Q gatekeeper mutant line was ∼20-fold higher than
with wild type parasites revealing that the primary target of
these compounds was actually PKG (Chapman et al., 2014;
Green et al., 2015).
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Recently, a team of scientists set out to identify the target
of a tri-substituted imidazole (MMV030084, compound 12,
Figure 1) that was previously shown to have activity against
P. falciparum blood stages in a high throughput screen of a GSK
library of around two million compounds (Gamo et al., 2010).
Further characterization of the activity profile showed that the
compound had activity specifically against late stage P. falciparum
blood stages with EC50 values of 109 and 120 nM against two
different lab isolates, male gamete formation (EC50 = 141 nM)
and invasion of hepatocytes by sporozoites (EC50 = 199 nM).
A range of approaches including chemoproteomics and the use of
transgenic P. falciparum parasites identified PKG as the primary
target of this compound which is consistent with the known
essential roles of PKG at all of these life cycle stages. A particularly
interesting aspect of the study was that resistance-selection
experiments with MMV030084 (12) did not generate highly
resistant mutants (Vanaerschot et al., 2020). One might anticipate
that highly resistant parasites could readily be generated by
selection of a mutant under PKG inhibitor pressure where the
gatekeeper threonine of PKG might be replaced by a bulkier
residue. However, this did not prove to be the case in either
this study or our own unpublished work in partnership with
the Tres Cantos Open lab Foundation using the imidazopyridine
ML10 (compound 3, Figure 1). Reasons for this could include
the fact that at least two base pairs would need to mutate to
change the gatekeeper threonine to e.g., a glutamine and also
that a threonine/glutamine substitution will likely have a fitness
cost because although the PKG transgenic T618Q line is viable
and can progress through the life cycle, we have shown that the
kinetics of the PKG mutant enzyme are less favorable than wild
type PKG with a ∼4-fold increase in Km value for ATP but a
similar Vmax (Fang et al., 2018). Importantly, drug pressure using
either ML10 (Cabrera et al., 2018) or MMV030084 (12) did not
result in any mutation in the PKG sequence in either study.
Vanaerschot and colleagues were able to select parasites with only
low-level resistance to 12 which primarily relied on mutations
in another protein kinase (tyrosine kinase-like protein 3) which
is itself not a target of the compound (Vanaerschot et al., 2020).
Together, the findings of this study strengthen the case for PKG
as an antimalarial target worthy of additional study, not least
because it appears to be a resistance-refractory target.
Apart from ATP-competitive inhibitors, cGMP analogs have
also recently been explored as potential anti-malarials. It has
been shown using biochemical and biophysical approaches that
8-NBD-cGMP, although having a similar affinity to cGMP, is
a P. falciparum PKG antagonist with a 10-fold reduction of
activation of PKG compared to cGMP (Byun et al., 2020). The
effects on the parasite have so far not been reported.
CONCLUSION
PKG has emerged as an exciting potential antimalarial drug
target, but at a time when there are a number of other excellent
targets that are being progressed and that are undergoing pre-
clinical testing and clinical trials. Time will tell whether PKG
inhibitors will be pursued in future pre-clinical testing and
beyond and will likely depend on how many of the more
advanced candidates are rolled out as components of new
antimalarial combination treatments.
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